After treatment with bevacizumab, CCL28 expression showed a log2 fold change of 1.258 compared to baseline, with a corresponding p-value of 0.0152, as depicted in Fig. 1A. After anti-angiogenesis therapy, tumor cells often experience a state of ischemia and hypoxia. The gene discussed is CCL28; the disease is neoplasm.